검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adjuvant IM Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | CGT |
Overview Target | MPS IIIA |
Overview Indication | MPS IIIA; Sanfilippo Syndrome |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target Mendelian randomization (MR), mediation MR, transcriptome-based machine learning, and single-cell RNA-seq were integrated to prioritize targets and pathway |
MoA Biomarker | HER2-Positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.. The discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associate… |
Toxicology CRS | Reported |
Clinical PFS | 17 |
Clinical OS | 17 |
Clinical Result source | ClinicalTrials.gov NCT02716974 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adjuvant IM Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | CGT |
Overview Target | MPS IIIA |
Overview Indication | MPS IIIA; Sanfilippo Syndrome |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target Mendelian randomization (MR), mediation MR, transcriptome-based machine learning, and single-cell RNA-seq were integrated to prioritize targets and pathway |
MoA Biomarker | HER2-Positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.. The discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associate… |
Toxicology CRS | Reported |
Clinical PFS | 17 |
Clinical OS | 17 |
Clinical Result source | ClinicalTrials.gov NCT02716974 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교